Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot
Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.
Pharma & Biotech
Pharma & Biotech
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.